SRL3 Antibody

What is SSTR3 and what cellular functions does it regulate?

Somatostatin Receptor 3 (SSTR3) is a G protein-coupled receptor that specifically binds somatostatin-14 and somatostatin-28 peptides. SSTR3 functions primarily through pertussis toxin-sensitive G proteins to inhibit adenylyl cyclase activity . This receptor is also known by several alternative names including SS-3-R, SS3-R, SS3R, SST3, and SSR-28 . SSTR3 plays critical roles in neuroendocrine signaling pathways and has been implicated in multiple physiological processes including hormone secretion regulation and cellular proliferation. Understanding SSTR3 distribution and function is particularly relevant for research into pancreatic function, as the receptor shows notable expression in pancreatic islets .

What types of SSTR3 antibodies are available for research applications?

Research-grade SSTR3 antibodies are available in multiple formats, with the most common being:

• Polyclonal antibodies: Such as rabbit polyclonal antibodies (e.g., ab28680) generated against synthetic peptides corresponding to specific amino acid sequences (typically within human SSTR3 aa 350-400) .

• Monoclonal antibodies: Including mouse monoclonal anti-human SSTR3 antibodies (e.g., MAB7018) which offer higher specificity for targeted epitopes .

Each antibody type offers distinct advantages depending on the experimental application, with polyclonals providing robust signal amplification through multiple epitope recognition, while monoclonals deliver higher specificity and batch-to-batch consistency.

What are the validated applications for SSTR3 antibodies?

SSTR3 antibodies have been validated for several research applications with varying levels of optimization:

The choice of application should be guided by the specific research question and experimental design considerations.

What are the critical factors for optimizing SSTR3 antibody performance in immunohistochemistry?

When using SSTR3 antibodies for immunohistochemistry applications, researchers should consider the following methodological factors:

• Tissue preparation: Optimal fixation protocols are essential for SSTR3 epitope preservation. Paraffin-embedded sections (IHC-P) have been validated with specific SSTR3 antibodies .

• Antibody dilution optimization: Empirical determination of optimal dilution is crucial, with published protocols suggesting a 1:2500 dilution for certain SSTR3 antibodies on human pancreatic islet tissues .

• Antigen retrieval methods: Heat-induced epitope retrieval techniques may be necessary to expose SSTR3 epitopes masked during fixation.

• Detection system selection: Secondary antibody selection and visualization method should be optimized based on the expected expression level of SSTR3 in target tissues.

• Controls implementation: Include both positive controls (known SSTR3-expressing tissues like pancreatic islets) and negative controls (either isotype controls or SSTR3-negative tissues) to validate staining specificity.

How can researchers effectively employ SSTR3 antibodies in flow cytometry studies?

Successful implementation of SSTR3 antibodies in flow cytometry requires attention to several methodological considerations:

• Cell preparation protocol: Single-cell suspensions must maintain membrane integrity to preserve SSTR3 surface expression.

• Titration of antibody concentration: For optimal signal-to-noise ratio, researchers should use approximately 2.5 μg antibody per 10^6 cells as a starting point for titration experiments .

• Appropriate controls: Use of isotype controls (e.g., MAB003) is essential for setting proper gating strategies and distinguishing specific from non-specific binding .

• Secondary antibody selection: When using unconjugated primary antibodies, selection of appropriate fluorophore-conjugated secondary antibodies (e.g., Allophycocyanin-conjugated Anti-Mouse IgG) is critical .

• Live/dead discrimination: Inclusion of viability dyes helps eliminate false-positive results from non-specific antibody binding to dead or dying cells.

The PC-3 human prostate cancer cell line has been validated as a positive control for SSTR3 expression analysis by flow cytometry .

What strategies should be employed for validation of SSTR3 antibody specificity?

Rigorous validation of SSTR3 antibody specificity is essential for generating reliable research data. Researchers should implement a multi-faceted validation approach:

• Western blot analysis: Confirm antibody recognizes a protein of the expected molecular weight for SSTR3.

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining.

• Knockout/knockdown controls: Compare staining patterns between wild-type and SSTR3-deficient samples.

• Cross-species reactivity assessment: Test antibody performance across relevant species based on sequence homology predictions.

• Orthogonal detection methods: Correlate antibody-based detection with alternative methods such as in situ hybridization to confirm expression patterns.

• Cross-platform validation: Compare results across multiple applications (e.g., IHC, flow cytometry) to ensure consistent detection patterns.

How can SSTR3 antibodies be integrated with advanced immunophenotyping platforms?

The evolution of immunophenotyping technologies offers new opportunities for SSTR3 research:

• CyTOF applications: SSTR3 antibodies that are CyTOF-ready can be metal-labeled for high-dimensional phenotyping in complex tissue microenvironments . This approach requires antibodies free from carrier proteins that might interfere with metal conjugation.

• Multiplexed immunofluorescence: Integration of SSTR3 antibodies into multiplexed panels allows simultaneous assessment of SSTR3 expression alongside other markers.

• Single-cell analysis workflows: Correlation of SSTR3 protein expression with transcriptomic data at single-cell resolution can provide insights into receptor heterogeneity across cell populations.

What are the considerations for applying SSTR3 antibodies in tumor microenvironment research?

Tumor microenvironment research represents a growing application area for SSTR3 antibodies:

• Tumor-infiltrating lymphocyte analysis: Similar to approaches used in B-cell repertoire analysis , SSTR3 expression on immune cells within tumors can be assessed.

• Neuroendocrine tumor characterization: SSTR3 expression profiling in tumor tissues can inform potential therapeutic targeting strategies.

• Receptor internalization dynamics: Antibody-based tracking of SSTR3 internalization following ligand binding can provide insights into receptor trafficking mechanisms.

• Spatial distribution analysis: Advanced imaging techniques combined with SSTR3 antibodies can reveal spatial relationships between SSTR3-expressing cells and other components of the tumor microenvironment.

How should researchers address common challenges with SSTR3 antibody applications?

Experimental challenges with SSTR3 antibodies can be resolved through systematic troubleshooting:

• High background signal in immunohistochemistry:

  • Optimize blocking conditions using appropriate blocking reagents

  • Increase washing duration and volume

  • Further dilute primary antibody

  • Reduce secondary antibody concentration

• Weak or absent signal:

  • Verify SSTR3 expression in selected sample type

  • Optimize antigen retrieval methods

  • Reduce antibody dilution

  • Extend primary antibody incubation time

  • Consider signal amplification systems

• Non-specific binding:

  • Validate antibody specificity through controls

  • Adjust blocking conditions

  • Pre-adsorb antibody if cross-reactivity is suspected

What approaches can increase sensitivity of SSTR3 detection in low-expression contexts?

For tissues or cells with low SSTR3 expression levels, consider these sensitivity-enhancing strategies:

• Signal amplification technologies: Implement tyramide signal amplification or similar approaches to enhance detection of low-abundance receptors.

• Proximity ligation assays: These techniques can amplify signals when SSTR3 interacts with binding partners.

• Surface plasmon resonance (SPR): While primarily used for other antibody applications , SPR-based detection methods can provide highly sensitive detection of antibody-antigen interactions.

• Sample enrichment: When possible, enrich for SSTR3-expressing cell populations prior to analysis.

How might SSTR3 antibody applications evolve with advancing immunological techniques?

Drawing parallels from recent advances in immunological research methodologies , several promising directions for SSTR3 antibody applications can be anticipated:

• Integration with antibody repertoire analysis: Similar to approaches used for tumor-infiltrating B cells , SSTR3 antibodies could be incorporated into comprehensive receptor profiling strategies.

• Development of bispecific antibody tools: Creation of bispecific antibodies targeting SSTR3 and complementary markers could enable novel functional studies.

• Application of SPR-based detection platforms: The advantages of surface plasmon resonance for direct antibody detection with reduced complexity and variability could be adapted for SSTR3 research.

• Implementation in point-of-care devices: Similar to developments for other therapeutic antibodies , SSTR3 antibody-based diagnostics might transition to rapid on-site analysis platforms.

These evolving methodologies highlight the continuing importance of SSTR3 antibody tools in advancing our understanding of somatostatin receptor biology and potential therapeutic applications.